Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan

por Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa Y., Seki, Naomi M., Omoto, Shinya, Igarashi, Kenji, Ariyasu, Mari
Publicado 2023

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings

por Iwata, Satoshi, Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa, Homma, Tomoyuki, Omoto, Shinya, Igarashi, Kenji, Ariyasu, Mari
Publicado 2022

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study

por Shinkai, Masaharu, Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa Yokokawa, Seki, Naomi M., Omoto, Shinya, Shinoda, Masahiro, Sato, Takashi, Ishii, Naoki, Igarashi, Kenji, Ariyasu, Mari
Publicado 2022